# Metabolic Peptide FAQ — MOTS-c, Semaglutide, Tesamorelin — Swe Peptider

> Frequently asked questions about three Metabolic & Weight Research peptides — MOTS-c, semaglutide, and tesamorelin — answered plainly from the cited literature, evidence gaps included.

Direct answers to the questions readers most often bring to MOTS-c, semaglutide, and tesamorelin, cited where evidence exists and flagged plainly where it does not.

## What does the MOTS-c peptide do?

MOTS-c is a 16-amino-acid peptide encoded within mitochondrial DNA that, in cell and animal studies, activates AMP-activated protein kinase (AMPK) — a cellular energy sensor — by inhibiting folate-cycle enzymes involved in purine synthesis, and separately binds casein kinase 2 directly, with effects on skeletal-muscle glucose uptake and prevention of muscle atrophy in mouse models [1]. Under metabolic stress it also moves from the mitochondrion into the cell nucleus to help regulate antioxidant-response genes [5]. All of this has been demonstrated in cells and mice; there is no completed human trial testing what exogenous MOTS-c does in people, so any claim about what it 'does' in a person is an extrapolation from that animal and cell-culture work, not a directly tested human finding.

## What are the negative side effects of MOTS-c?

There is no published human safety data for exogenous MOTS-c, because there is no completed human intervention trial of it — so a specific, evidence-based side-effect list cannot honestly be given [3]. What can be said is contextual: MOTS-c is sold only as an unregulated research chemical, so purity and identity vary by supplier; it is treated as a prohibited peptide in competitive sport; and rodent dosing figures (roughly 0.5-15 mg/kg/day) provide no basis for predicting a human dose or its effects. Any specific human side-effect claim circulating online is not backed by a controlled study at this time.

## Is MOTS-c legal to buy?

MOTS-c is not FDA-approved for any human use. It is legally sold in the United States as a research chemical labeled for laboratory use only, which is a different legal category from an approved or prescription drug — it does not mean the compound has been evaluated for human safety or efficacy. Athletes in tested sports should also be aware that anti-doping authorities treat MOTS-c as a prohibited peptide under hormone-and-metabolic-modulator categories, independent of its research-chemical sales status.

## How often do you inject MOTS-c?

There is no clinically established or trial-tested human dosing schedule for MOTS-c, because no completed human intervention trial has generated one [3]. Frequencies circulating in research-use communities are not derived from published pharmacokinetic data — no human half-life or bioavailability figure for MOTS-c has been published — so this desk does not report or endorse a schedule. This is a case where the absence of an answer is itself the accurate answer.

## What is semaglutide?

Semaglutide is a synthetic peptide that acts as a GLP-1 receptor agonist, mimicking glucagon-like peptide-1, a hormone the gut releases after eating. It is FDA-approved for type 2 diabetes, chronic weight management, reduction of cardiovascular events in adults with established cardiovascular disease and excess weight, and (since 2025) metabolic dysfunction-associated steatohepatitis, given as a once-weekly injection or once-daily oral tablet [9][10]. It is a prescription medicine, not a research-only compound, and it is the most extensively trialed compound on this desk.

## What is semaglutide used for?

FDA-approved uses include lowering blood glucose in type 2 diabetes, reducing body weight in chronic weight management at the higher dose, and reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity [8][9]. It has also been studied for kidney-outcome reduction in type 2 diabetes with chronic kidney disease, where it reduced the primary kidney composite by 24% versus placebo in a dedicated trial [7]. All of these are documented, trial-tested uses; recreational or off-label extrapolations beyond them are not covered by the same evidence.

## How does semaglutide work?

It activates GLP-1 receptors: in the pancreas, boosting glucose-dependent insulin release and suppressing glucagon; in the stomach, slowing gastric emptying; and in the brain, acting on hypothalamic and brainstem appetite circuits to reduce food intake [11]. The glucose-dependent nature of the insulin effect is why it carries a relatively low hypoglycemia risk when used alone. GLP-1 receptors in the heart and kidney are also implicated in the drug's separately demonstrated cardiovascular and kidney benefits [7][8].

## How does semaglutide work for weight loss?

The weight effect is largely centered in the brain, not the gut. Semaglutide reaches the hypothalamic arcuate nucleus and the brainstem area postrema, activating neurons that signal fullness and suppressing neurons that drive hunger, which reduces overall food intake and, according to patient reports, the intrusive background preoccupation with food some call 'food noise' [11]. In the pivotal trial that established the indication, this translated into a mean 14.9% body-weight reduction at 68 weeks versus 2.4% with placebo [9] — though a subsequent head-to-head trial found a newer dual-receptor agonist produced a larger effect on the same measure [6].

## What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), modified to resist rapid enzymatic breakdown. It is FDA-approved for one specific indication: reducing excess visceral fat in HIV-infected adults with antiretroviral-associated lipodystrophy [14]. It works by stimulating the pituitary gland to release the body's own growth hormone rather than by supplying growth hormone directly.

## What does tesamorelin do?

By stimulating pulsatile release of endogenous growth hormone, tesamorelin raises IGF-1 and promotes lipolysis with a demonstrated preference for visceral fat. In its pivotal population — HIV-associated lipodystrophy — pooled trial data show reductions in visceral fat, trunk fat, and liver fat, alongside an increase in lean body mass [13][15]. Its demonstrated effects are specific to that trial population; extending the claim to general fat loss in people without HIV-associated lipodystrophy is plausible by mechanism but not established by trials of comparable size in that broader group.

## How does tesamorelin work?

Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, triggering the same signaling cascade the body's own GHRH uses to stimulate growth-hormone synthesis and pulsatile release. The resulting growth hormone drives hepatic IGF-1 production, and GH and IGF-1 together promote lipolysis, preferentially in visceral fat [16]. Because it amplifies the body's natural GH rhythm rather than supplying a flat, continuous dose of hormone, its metabolic profile is described as distinct from giving recombinant growth hormone directly — though the practical size of that difference depends on what a given trial actually measured.

## Will tesamorelin help me lose belly fat?

In its FDA-approved population — HIV-infected adults with antiretroviral-associated lipodystrophy — tesamorelin has repeatedly and significantly reduced visceral (deep abdominal) fat in randomized trials, with the effect reversing once treatment stops [13][15][17]. Outside that specific population, there is no comparably sized trial establishing the same effect; the mechanism is plausible, but plausibility is not the same claim as demonstrated evidence in a general population. This page does not recommend tesamorelin, or any dose of it, for weight loss outside its tested indication.

---

An independent audit of the metabolic-peptide literature that says plainly what's proven, what's preliminary, and what's still guesswork.